Matt Henriksen

But, you know, IVL is still such a new topic for these listeners.

And, you know, first off, people, IVL is being intravascular lithotripsy.

Let's start with kind of an overview of that technology.

And, you know, we talked about Shockwave as kind of being the front runner right now.

Let's start just kind of with their technology as kind of the traditional technology.

How does lithotripsy actually work?

Okay.

And so then, you know, walk the listener through then the difference between those two mechanisms, the sonic wave and your pulse tile technology.

Because from the previous episode, that was the differentiating technology between you and some of these other IVL technologies out there.

Gotcha.

Okay.

And so what does that, how does the pulsatile technology, how is that being designed to kind of address any of the shortfalls of the sonic wave technology?

And that's because you have to cross the lesion to get completely through to be able to then expand it and then be able to break the lesion then, correct?

Yeah.

And so then let's, let's dive into then just the results because you have, you know, as part of the development of any medical technology, you need to be able to prove the clinical results and you have therefore designed and you've enrolled and now you have the data out for the power PAD2 trial.

Let's start with just that process because when we were speaking a year and a half ago, you had not started the enrollment.

We were just talking about the design and

What was the process to getting that trial initiated first off?

Because you had the preliminary data and what was that showing you?

Let's take a step back because, you know, we talked about your background and how you came to be the chairman of AVS in the previous episode.